panalo999
Election observers reveal nation's politics on global stageSurge in warm clothes sales as Sargodha faces chilly weather
None
Late kickoff return TDs by Turpin and Thomas spark the Cowboys as they end their 5-game skid
By Michelle Marchante, Miami Herald (TNS) MIAMI — As her students finished their online exam, Arlet Lara got up to make a cafe con leche . Her 16-year-old son found her on the kitchen floor. First, he called Dad in a panic. Then 911. “I had a stroke and my life made a 180-degree turn,” Lara told the Miami Herald, recalling the medical scare she experienced in May 2020 in the early months of the COVID pandemic. “The stroke affected my left side of the body,” the North Miami woman and former high school math teacher said. Lara, an avid runner and gym goer, couldn’t even walk. “It was hard,” the 50-year-old mom said. After years of rehabilitation therapy and a foot surgery, Lara can walk again. But she still struggles with moving. This summer, she became the first patient in South Florida to get an implant of a new and only FDA-approved nerve stimulation device designed to help ischemic stroke survivors regain movement in their arms and hands. This first procedure was at Jackson Memorial Hospital in Miami. Lara’s rehab was at at the Christine E. Lynn Rehabilitation Center for The Miami Project to Cure Paralysis, part of a partnership between Jackson Health System and UHealth. Every year, thousands in the United States have a stroke , with one occurring every 40 seconds, according to the U.S. Centers for Disease Control and Prevention. The majority of strokes are ischemic, often caused by blood clots that obstruct blood flow to the brain. For survivors, most of whom are left with some level of disability, the Vivistim Paired VNS System, the device implanted in Lara’s chest, could be a game changer in recovery, said Dr. Robert Starke, a UHealth neurosurgeon and interventional neuroradiologist. He also serves as co-director of endovascular neurosurgery at Jackson Memorial Hospital, part of Miami-Dade’s public hospital system. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant designed to help stroke survivors regain function in their arms, goes through exercises while her therapist activates the device during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA- approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) The Vivistim Paired VNS System is a small pacemaker-like device implanted in the upper chest and neck area. Patients can go home the same day. The U.S. Food and Drug Administration approved the stroke rehabilitation system in 2021 to be used alongside post-ischemic stroke rehabilitation therapy to treat moderate to severe mobility issues in hands and arms. Lara’s occupational therapist can activate the device during rehabilitation sessions to electrically stimulate the vagus nerve, which runs from the brain down to the abdomen and regulates various parts of the body’s nervous system. The electrical stimulation rewires the brain to improve a stroke survivor’s ability to move their arms and hands. Lara also has a magnet she can use to activate the device when she wants to practice at home. Her therapy consists of repetitive tasks, including coloring, pinching cubes and grabbing and releasing cylindrical shapes. After several weeks of rehabilitation therapy with the device, Lara has seen improvement. “Little by little, I’m noticing that my hand is getting stronger. I am already able to brush my teeth with the left hand,” she told the Miami Herald in September. Since then, Lara has finished the initial six-week Vivitism therapy program, and is continuing to use the device in her rehabilitation therapy. She continues to improve and can now eat better with her left hand and can brush her hair with less difficulty, according to her occupational therapist, Neil Batungbakal. Lara learned about the device through an online group for stroke survivors and contacted the company to inquire. She then connected them with her Jackson medical team. Now a year later, the device is available to Jackson patients. So far, four patients have received the implant at Jackson. Starke sees the device as an opportunity to help bring survivors one step closer to regaining full mobility. Strokes are a leading cause of disability worldwide. While most stroke survivors can usually recover some function through treatment and rehabilitation, they tend to hit a “major plateau” after the first six months of recovery, he said. Vivistim, when paired with rehabilitation therapy, could change that. Jackson Health said results of a clinical trial published in the peer-reviewed medical journal The Lancet in 2021 showed that the device, “when paired with high-repetition, task-specific occupational or physical therapy, helps generate two to three times more hand and arm function for stroke survivors than rehabilitation therapy alone.” The device has even shown to benefit patients 20 years from their original stroke, according to Starke. “So now a lot of these patients that had strokes 10-15 years ago that thought that they would never be able to use their arm in any sort of real functional way are now able to have a real meaningful function, which is pretty tremendous,” Starke said. Vivistim’s vagus-nerve stimulation technology was developed by researchers at the University of Texas at Dallas’ Texas Biomedical Device Center and is being sold commercially by Austin-based MicroTransponder, a company started by university graduates. Similar devices are used to treat epilepsy and depression . For Lara, the device is a new tool to help her recovery journey. “Everything becomes a challenge so we are working with small things every day because I want to get back as many functions as possible,” Lara said. Patients interested in Vivistim should speak with their doctor to check their eligibility. The FDA said patients should make sure to discuss any prior medical history, including concurrent forms of brain stimulation, current diathermy treatment, previous brain surgery, depression, respiratory diseases and disorders such as asthma, and cardiac abnormalities. “Adverse events included but were not limited to dysphonia (difficulty speaking), bruising, falling, general hoarseness, general pain, hoarseness after surgery, low mood, muscle pain, fracture, headache, rash, dizziness, throat irritation, urinary tract infection and fatigue,” the FDA said. MicroTransponder says the device is “covered by Medicare, Medicaid, and private insurance with prior authorization on a case-by-case basis.” To learn more about the device, visit vivistim.com. ©2024 Miami Herald. Visit at miamiherald.com. Distributed by Tribune Content Agency, LLC.Moreover, the dialogue touched upon the impact of digitalization and data analytics on decision-making processes in the commercial real estate sector. Zhou Haichao spoke about the transformative power of big data and artificial intelligence in optimizing property management and enhancing tenant engagement. Zhao Xiuchi shared examples of how data-driven insights are revolutionizing the way developers strategize and market their projects, underlining the importance of leveraging technology for competitive advantage.As the clock ticked closer to the A-share market opening, anticipation reached a fever pitch. Traders eagerly awaited the bell to signal the start of trading, poised to capitalize on the positive momentum generated by the Gold Dragon Index's resurgence. The atmosphere was electric, with traders strategizing their moves and keeping a close eye on market fluctuations.
The success of "Wilderness Origins" and its collaboration with Sony exemplify the power of partnerships in the gaming industry, highlighting the potential for mutual growth and innovation. By combining their strengths and resources, Tencent and Sony have set the stage for a dynamic and fruitful collaboration that is poised to redefine the mobile gaming landscape.Wild first season in expanded Big 12 comes down to final weekendREDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec 9, 2024-- C3.ai, Inc. (“C3 AI,” “C3,” or the “Company”) (NYSE: AI), the Enterprise AI application software company, today announced financial results for its fiscal second quarter ended October 31, 2024. “We had an outstanding quarter with strong top- and bottom-line performance to mark our seventh consecutive quarter of accelerating revenue growth,” said Thomas M. Siebel, Chairman and CEO, C3 AI. “It is difficult to overstate the potential of the Microsoft–C3 AI strategic alliance,” said Siebel. “By establishing C3 AI as a preferred AI application provider on Azure and creating a Microsoft-scale go-to-market engine, we’re making it easy for businesses to adopt and deploy C3 AI applications. This is an inflection point for Enterprise AI, driving growth.” Fiscal Second Quarter 2025 Financial Highlights Microsoft Azure Strategic Alliance Partner Network C3 AI reinforced its leadership in Enterprise AI, strengthened by a thriving partner ecosystem to accelerate Enterprise AI adoption. Business Highlights C3 AI had continuing momentum with significant Federal and commercial successes and strengthened strategic partnerships. Federal Momentum Federal business demonstrated strong execution, securing key wins and expansions across multiple agencies. C3 Generative AI C3 AI further strengthens its competitive edge in generative AI, affirming its market leadership. Financial Outlook: The Company’s guidance includes GAAP and non-GAAP financial measures. The following table summarizes C3 AI’s guidance for the third quarter of fiscal 2025 and full-year fiscal 2025: (in millions) Third Quarter Fiscal 2025 Guidance Full Year Fiscal 2025 Guidance Total revenue $95.5 - $100.5 $378.0 - $398.0 Non-GAAP loss from operations $(38.6) - $(46.6) $(105.0) - $(135.0) A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding, and the potential variability of, expenses that may be incurred in the future. Stock-based compensation expense-related charges, including employer payroll tax-related items on employee stock transactions, are impacted by the timing of employee stock transactions, the future fair market value of our common stock, and our future hiring and retention needs, all of which are difficult to predict and subject to constant change. We have provided a reconciliation of GAAP to non-GAAP financial measures in the financial statement tables for our historical non-GAAP results included in this press release. Our fiscal year ends April 30, and numbers are rounded for presentation purposes. Conference Call Details What: C3 AI Second Quarter Fiscal 2025 Financial Results Conference Call When: Monday, December 9, 2024 Time: 2:00 p.m. PT / 5:00 p.m. ET Participant Registration: https://register.vevent.com/register/BI383ae1e1c80b4221a65de6c2c2baf582 (live) Webcast: https://edge.media-server.com/mmc/p/xf8dudjw (live and replay) Investor Presentation Details An investor presentation providing additional information and analysis can be found at our investor relations page at ir.c3.ai . Statement Regarding Use of Non-GAAP Financial Measures The Company reports the following non-GAAP financial measures, which have not been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP financial measures. Other Information Professional Services Revenue Our professional services revenue includes service fees and prioritized engineering services. Service fees include revenue from services such as consulting, training, and paid implementation services. For service fees, revenue is typically recognized over time as the services are performed. Prioritized engineering services are undertaken when a customer requests that we accelerate the design, development, and delivery of software features and functions that are planned in our future product roadmap. When we agree to this, we negotiate an agreed upon fee to accelerate the development of the software. When the software feature is delivered, it becomes integrated to our core product offering, is available to all subscribers of the underlying software product, and enhances the operation of that product going forward. Such prioritized engineering services result in production-level computer software – compiled code that enhances the functionality of our production products – which is available for our customers to use over the life of their software licenses. Per Accounting Standards Codification (ASC) 606, Prioritized engineering services revenue is recognized as professional services over the period in which the software development is completed. Total professional services revenue consists of: Three Months Ended October 31, Six Months Ended October 31, 2024 2023 2024 2023 (in thousands) (in thousands) Prioritized engineering services $ 9,661 $ 4,852 $ 20,310 $ 13,100 Service fees 3,515 1,928 6,623 4,690 Total professional services revenue $ 13,176 $ 6,780 $ 26,933 $ 17,790 Use of Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding our market leadership position, anticipated benefits from our partnerships, financial outlook, our sales and customer opportunity pipeline including our industry diversification, the expected benefits of our offerings (including the potential benefits of our C3 Generative AI offerings), and our business strategies, plans, and objectives for future operations. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks and uncertainties, including our history of losses and ability to achieve and maintain profitability in the future, our historic dependence on a limited number of existing customers that account for a substantial portion of our revenue, our ability to attract new customers and retain existing customers, market awareness and acceptance of enterprise AI solutions in general and our products in particular, the length and unpredictability of our sales cycles and the time and expense required for our sales efforts. Some of these risks are described in greater detail in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q for the fiscal quarters ended July 31, 2024 and, when available, October 31, 2024, although new and unanticipated risks may arise. The future events and trends discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements, or events and circumstances reflected in the forward-looking statements will occur. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date of this press release to conform these statements to actual results or revised expectations. About C3.ai, Inc. C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software company. C3 AI delivers a family of fully integrated products including the C3 AI Platform, an end-to-end platform for developing, deploying, and operating enterprise AI applications, C3 AI applications, a portfolio of industry-specific SaaS enterprise AI applications that enable the digital transformation of organizations globally, and C3 Generative AI, a suite of domain-specific generative AI offerings for the enterprise. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) Three Months Ended October Six Months Ended October 31, 2024 2024 2023 2024 2023 Revenue Subscription (1) $ 81,162 $ 66,449 $ 154,618 $ 127,801 Professional services (2) 13,176 6,780 26,933 17,790 Total revenue 94,338 73,229 181,551 145,591 Cost of revenue Subscription 35,038 30,937 68,330 61,371 Professional services 1,460 1,179 3,215 2,558 Total cost of revenue 36,498 32,116 71,545 63,929 Gross profit 57,840 41,113 110,006 81,662 Operating expenses Sales and marketing (3) 55,643 49,895 107,768 93,780 Research and development 55,715 50,399 108,642 101,267 General and administrative 21,770 20,215 41,470 40,104 Total operating expenses 133,128 120,509 257,880 235,151 Loss from operations (75,288 ) (79,396 ) (147,874 ) (153,489 ) Interest income 9,560 10,480 19,563 20,602 Other income (expense), net 13 (638 ) 41 (877 ) Loss before provision for income taxes (65,715 ) (69,554 ) (128,270 ) (133,764 ) Provision for income taxes 257 226 529 374 Net loss $ (65,972 ) $ (69,780 ) $ (128,799 ) $ (134,138 ) Net loss per share attributable to Class A and Class B common stockholders, basic and diluted $ (0.52 ) $ (0.59 ) $ (1.02 ) $ (1.15 ) Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted 127,870 118,656 126,434 117,125 (1) Including related party revenue of $10,581 for the six months ended October 31, 2023. (2) Including related party revenue of $5,804 for the six months ended October 31, 2023. (3) Including related party sales and marketing expense of $810 for the six months ended October 31, 2023. C3.AI, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except for share and per share data) (Unaudited) October 31, 2024 April 30, 2024 Assets Current assets Cash and cash equivalents $ 121,274 $ 167,146 Marketable securities 609,100 583,221 Accounts receivable, net of allowance of $486 and $359 as of October 31, 2024 and April 30, 2024, respectively 159,987 130,064 Prepaid expenses and other current assets 27,458 23,963 Total current assets 917,819 904,394 Property and equipment, net 84,198 88,631 Goodwill 625 625 Other assets, non-current 43,647 44,575 Total assets $ 1,046,289 $ 1,038,225 Liabilities and stockholders’ equity Current liabilities Accounts payable $ 20,611 $ 11,316 Accrued compensation and employee benefits 41,755 44,263 Deferred revenue, current 35,663 37,230 Accrued and other current liabilities 23,979 9,526 Total current liabilities 122,008 102,335 Deferred revenue, non-current 127 1,732 Other long-term liabilities 65,193 60,805 Total liabilities 187,328 164,872 Commitments and contingencies Stockholders’ equity Class A common stock 125 120 Class B common stock 3 3 Additional paid-in capital 2,077,044 1,963,726 Accumulated other comprehensive income (loss) 521 (563 ) Accumulated deficit (1,218,732 ) (1,089,933 ) Total stockholders’ equity 858,961 873,353 Total liabilities and stockholders’ equity $ 1,046,289 $ 1,038,225 C3.AI, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Six Months Ended October 31, 2024 2023 Cash flows from operating activities: Net loss $ (128,799 ) $ (134,138 ) Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization 6,092 6,220 Non-cash operating lease cost 203 454 Stock-based compensation expense 111,721 104,049 Accretion of discounts on marketable securities (7,618 ) (8,755 ) Other 418 — Changes in operating assets and liabilities Accounts receivable (1) (30,051 ) (8,567 ) Prepaid expenses, other current assets and other assets (2) (1,993 ) (665 ) Accounts payable (3) 9,294 (2,918 ) Accrued compensation and employee benefits (4,815 ) (2,551 ) Operating lease liabilities (1,215 ) 7,804 Other liabilities (4) 19,284 1,709 Deferred revenue (5) (3,172 ) (7,296 ) Net cash used in operating activities (30,651 ) (44,654 ) Cash flows from investing activities: Purchases of property and equipment (1,739 ) (16,631 ) Capitalized software development costs — (2,750 ) Purchases of marketable securities (365,926 ) (489,871 ) Maturities and sales of marketable securities 348,750 412,554 Net cash used in investing activities (18,915 ) (96,698 ) Cash flows from financing activities: Proceeds from issuance of Class A common stock under employee stock purchase plan 5,009 5,055 Proceeds from exercise of Class A common stock options 4,472 10,163 Taxes paid related to net share settlement of equity awards (5,787 ) (9,686 ) Net cash provided by financing activities 3,694 5,532 Net decrease in cash, cash equivalents and restricted cash (45,872 ) (135,820 ) Cash, cash equivalents and restricted cash at beginning of period 179,712 297,395 Cash, cash equivalents and restricted cash at end of period $ 133,840 $ 161,575 Cash and cash equivalents $ 121,274 $ 149,009 Restricted cash included in other assets 12,566 12,566 Total cash, cash equivalents and restricted cash $ 133,840 $ 161,575 Supplemental disclosure of cash flow information—cash paid for income taxes $ 534 $ 281 Supplemental disclosures of non-cash investing and financing activities: Purchases of property and equipment included in accounts payable and accrued liabilities $ 117 $ 7,293 Right-of-use assets obtained in exchange for lease obligations (including remeasurement of right-of-use assets and lease liabilities due to changes in the timing of receipt of lease incentives) $ 1,345 $ 778 Vesting of early exercised stock options $ 216 $ 294 (1) Including changes in related party balances of $12,444 for the six months ended October 31, 2023. (2) Including changes in related party balances of $(810) for the six months ended October 31, 2023. (3) Including changes in related party balances of $248 for the six months ended October 31, 2023. (4) Including changes in related party balances of $(2,448) for the six months ended October 31, 2023. (5) Including changes in related party balances of $(46) for the six months ended October 31, 2023. C3.AI, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (In thousands, except percentages) (Unaudited) Three Months Ended October 31, Six Months Ended October 31, 2024 2023 2024 2023 Reconciliation of GAAP gross profit to non-GAAP gross profit: Gross profit on a GAAP basis $ 57,840 $ 41,113 $ 110,006 $ 81,662 Stock-based compensation expense (1) 8,311 8,993 16,719 17,509 Employer payroll tax expense related to employee stock-based compensation (2) 171 297 527 838 Gross profit on a non-GAAP basis $ 66,322 $ 50,403 $ 127,252 $ 100,009 Gross margin on a GAAP basis 61 % 56 % 61 % 56 % Gross margin on a non-GAAP basis 70 % 69 % 70 % 69 % Reconciliation of GAAP loss from operations to non-GAAP loss from operations: Loss from operations on a GAAP basis $ (75,288 ) $ (79,396 ) $ (147,874 ) $ (153,489 ) Stock-based compensation expense (1) 57,038 53,169 111,721 104,049 Employer payroll tax expense related to employee stock-based compensation (2) 1,090 1,274 2,362 3,774 Loss from operations on a non-GAAP basis $ (17,160 ) $ (24,953 ) $ (33,791 ) $ (45,666 ) Reconciliation of GAAP net loss per share to non-GAAP net loss per share: Net loss on a GAAP basis $ (65,972 ) $ (69,780 ) $ (128,799 ) $ (134,138 ) Stock-based compensation expense (1) 57,038 53,169 111,721 104,049 Employer payroll tax expense related to employee stock-based compensation (2) 1,090 1,274 2,362 3,774 Net loss on a non-GAAP basis $ (7,844 ) $ (15,337 ) $ (14,716 ) $ (26,315 ) GAAP net loss per share attributable to Class A and Class B common shareholders, basic and diluted $ (0.52 ) $ (0.59 ) $ (1.02 ) $ (1.15 ) Non-GAAP net loss per share attributable to Class A and Class B common shareholders, basic and diluted $ (0.06 ) $ (0.13 ) $ (0.12 ) $ (0.22 ) Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted 127,870 118,656 126,434 117,125 (1) Stock-based compensation expense for gross profits and gross margin includes costs of subscription and cost of professional services as follows. Stock-based compensation expense for loss from operations includes total stock-based compensation expense as follows: Three Months Ended October 31, Six Months Ended October 31, 2024 2023 2024 2023 Cost of subscription $ 7,827 $ 8,514 $ 15,521 $ 16,570 Cost of professional services 484 479 1,198 939 Sales and marketing 20,802 18,226 39,635 35,005 Research and development 17,999 16,685 36,430 33,718 General and administrative 9,926 9,265 18,937 17,817 Total stock-based compensation expense $ 57,038 $ 53,169 $ 111,721 $ 104,049 (2) Employer payroll tax expense related to employee stock-based compensation for gross profits and gross margin includes costs of subscription and cost of professional services as follows. Employer payroll tax expense related to employee stock-based compensation for loss from operations includes total employer payroll tax expense related to employee stock-based compensation as follows: Three Months Ended October 31, Six Months Ended October 31, 2024 2023 2024 2023 Cost of subscription $ 163 $ 282 $ 489 $ 791 Cost of professional services 8 15 38 47 Sales and marketing 450 463 922 1,468 Research and development 231 415 595 1,232 General and administrative 238 99 318 236 Total employer payroll tax expense $ 1,090 $ 1,274 $ 2,362 $ 3,774 Reconciliation of free cash flow to the GAAP measure of net cash used in operating activities: The following table below provides a reconciliation of free cash flow to the GAAP measure of net cash used in operating activities for the periods presented: Three Months Ended October 31, Six Months Ended October 31, 2024 2023 2024 2023 Net cash used in operating activities $ (38,693 ) $ (48,590 ) $ (30,651 ) $ (44,654 ) Less: Purchases of property and equipment (815 ) (5,293 ) (1,739 ) (16,631 ) Capitalized software development costs — (1,250 ) — (2,750 ) Free cash flow $ (39,508 ) $ (55,133 ) $ (32,390 ) $ (64,035 ) Net cash provided by (used in) investing activities $ 22,635 $ (11,898 ) $ (18,915 ) $ (96,698 ) Net cash provided by financing activities $ 3,512 $ 3,055 $ 3,694 $ 5,532 View source version on businesswire.com : https://www.businesswire.com/news/home/20241209723558/en/ CONTACT: Investor Contact ir@c3.aiC3 AI Public Relations Edelman Lisa Kennedy (415) 914-8336 pr@c3.ai KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SOFTWARE TECHNOLOGY ARTIFICIAL INTELLIGENCE SOURCE: C3.ai Copyright Business Wire 2024. PUB: 12/09/2024 04:05 PM/DISC: 12/09/2024 04:06 PM http://www.businesswire.com/news/home/20241209723558/en Copyright Business Wire 2024.
In a world often characterized by chaos and division, the story of Mrs. Thompson and the kind-hearted vendor stands as a beacon of light, illuminating the path towards a more compassionate and interconnected society. May we all be inspired by their example to extend a helping hand to those in need, forging bonds of empathy and understanding that transcend barriers and unite us in our shared humanity.Facing financial struggles and societal pressures, Wu Liufang's dreams often seemed out of reach. But she never gave up. With unwavering determination and a fierce resilience, she continued to pursue her passion, honing her skills and building her online presence one video at a time.A Bull Market Is Here: 2 Supercharged Stocks Down More Than 20% to Buy Right Now
In conclusion, the current status of Manchester United's Premier League title-winning squad from the 2012/2013 season serves as a poignant reminder of the passage of time and the inevitability of change in football. As players come and go, retire and move on to new challenges, the spirit of camaraderie and achievement that defined that championship-winning team lives on in the hearts of fans everywhere. The legacy of Manchester United's success endures, transcending individual players and moments to become a timeless symbol of excellence in the world of football.
Looking for a smartwatch packed with advanced features at a fraction of the price? Now is the perfect time to purchase the on , as it’s currently on offer at an astonishing 80% discount. This renowned smartwatch comes equipped with several compelling features that make it a must-have gadget for tech enthusiasts and fitness buffs alike. One of the standout features of the is its health and fitness tracking capabilities. With its integrated ECG monitor, SpO2 sensor, and blood pressure monitor, this watch provides an in-depth look at your health metrics. Whether you’re a seasoned athlete aiming to optimize your training or someone keen on maintaining a healthy lifestyle, this watch offers the tools you need for comprehensive health tracking. Moreover, the comes equipped with a sleek 1.4" Super AMOLED display that ensures a vivid and clear viewing experience. It doesn't just look good—it’s built to last, boasting military-grade durability and water resistance. This means you can take it along for a swim or through tough outdoor conditions without worry. For those who enjoy staying connected on the go, the Galaxy Watch 4 Classic’s LTE capabilities make it a standout choice. By simply contacting your carrier, you can set up this watch to function independently from your phone, making it more than just a fitness tracker—it becomes an essential communication tool. Plus, with features like Samsung Pay, you’re equipped to handle transactions effortlessly. In addition to its robust features, switching to a renewed product doesn’t mean sacrificing quality. Each unit of the has been tested and verified to ensure it meets manufacturer standards, ensuring reliability at a discounted price. This smartwatch is not just a purchase; it’s an investment in your wellness and connectivity. In conclusion, the opportunity to own the has never been better, especially with this 80% discount available on . From health tracking to staying connected, it covers all bases beautifully. Don’t miss out on owning this technological gem at a remarkable price today!